Surgical Stents: Rapid Development in the stents upsurges the market growth at a CAGR of 7.9%

Pune, India, April 3, 2022 /press release/- Market Research Future Published a Half Cooked Research Report on Global Surgical Stents Market Research Report.

Market Highlights

Market Scenario:

Stents are tiny tube like medical devices, which are placed into blood vessels or arteries to open the blockage in the vessels. They are primarily used in the treatment of cardiac and renal diseases. A number of people are suffering from cardiac and renal diseases, and the number is increasing continuously due to changing lifestyle, and lack of exercise. The global surgical stent market is driven by increasing prevalence of cardiac & renal diseases, rising diabetic population, and continuous innovation & introduction of new stents. However, the risk of infection, long approval time and higher cost holding the growth of the market. The global surgical stent market is projected to reach USD 20,437.3 Million by 2030 at 9.8% CAGR during the forecast period 2022-2030.

Segmentation:

The global surgical stents market is segmented into types, type of materials, application, and end users. On the basis of types, the market is segmented: cardiac stents, urinary stents, biliary stents, oesophageal stents, prostatic stents, and others. Cardiac stents are further segmented: self-expanding stents, balloon expanding stents, bio-engineered stents, dual therapy stents, artery stents, drug eluting stents, and others. Urinary stents are further segmented: open end stents, double pigtail stents, closed end stents, and multi loop stents. On the basis of materials, the market is segmented: metal, standard polymer, and biodegradable polymer. On the basis of applications, the market is segmented: cardiac diseases, urinary tract diseases, and others. On the basis of end users, the market is segmented into hospital, clinics, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Surgical Stents Market Research Report

Regional Analysis

America accounts for the largest share of global surgical stent market owing to the presence of an enormous patient population base. According to the Centers for Disease Control and Prevention, 9.3% of total America population is suffering from diabetes. Diabetes and obesity are the leading causes of cardiac and renal diseases. Due to increasing diabetic and obese population, America is witnessing rapid growth in the market. Europe has the second leading market of surgical stents which is followed by Asia Pacific. Asia Pacific is experiencing the highest growth for the surgical stents market in the globe. According to the WHO (2016), around 5% of the total Indian population is suffering from obesity. Increasing prevalence of cardiac diseases, rising obese, and geriatric population boosting the growth in Asia Pacific market. India and China dominate the market for surgical stents in Asia Pacific region.

Some of the major key player in the market are STI Laser Industries, Ltd (Israel), ELLA - CS, s.r.o. (Czech Republic), Medtronic (US), Boston Scientific Corporation (US), Laserage Technology corporation (US), amg International GmbH (Germany), Abbott (US), Angiocare (Netherlands), Meril Life Sciences Pvt. Ltd. (India), Elixir Medical Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun Melsungen AG(Germany), Medtronic (US), Amaranth Medical, Inc (US), Arterial Remodeling Technologies (US).

The global surgical stents market is experiencing extreme competition due to major companies are focusing on the development of biodegradable stents to overcome the disadvantages of other available stents. Some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.

Boston Scientific Corporation, headquartered in the US, is a global manufacturer and developer of medical devices. The company has adopted various strategies to sustain in the competitive market, for instance, new products launch. PROMUS Element Plus Stent, REBEL Stent System, SYNERGY Stent are some of the major products of the company. In 2015, worldwide sales of the company’s drug-eluting coronary stents were $1.074 billion as compared to $1.151 billion during 2014.

Abbott, headquartered in US, is one of the leading healthcare company. In June 2016, FDA has approved the Absorb bioresorbable Stent for heart. This stents is completely dissolve in the body and used in the treatment of heart complications. Company’s Esprit bioresorbable vascular scaffold is under clinical trials.

Medtronic, headquartered in UK, is a world's largest standalone medical device manufacturer. In 2015 company has develop Stent Graft System System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms. Earlier company’s Resolute Drug-Eluting Stent has shown a very good performance in Diabetic Patients with Heart Disease.